BIRMINGHAM, England, January 28 /PRNewswire/ -- The Binding Site Limited ("The Binding Site" or the "Company"), a privately-owned specialist U.K. diagnostics company, today announces the publication of the first international guidelines recommending first-line use of Freelite(TM) in the diagnosis and management of multiple myeloma, a cancer of cells in the bone marrow, and related plasma cell disorders.
The guidelines were written on behalf of the International Myeloma Working Group ("IMWG"), led by Dr. A Dispenzieri, Division of Hematology and Division of Laboratory Medicine, Mayo Clinic, USA, and will be published in Leukemia, a leading haematology and oncology journal, in February 2009.
Freelite is a unique assay, developed and marketed by The Binding Site, used for the diagnosis and monitoring of multiple myeloma (MM) and related disorders. Immunoglobulin free light chains (FLC) in serum are an important tumour marker present in patients suffering from MM and associated malignancies. The only test available for measuring serum FLC is The Binding Site's Freelite assay. To date, the test has been incorporated into clinical practice on the basis of published evidence. These new international guidelines have been written specifically to guide clinicians in the use of serum FLC measurements in their diagnosis and treatment of MM and related plasma cell disorders (PCD).
Commenting on the guidelines, Paul Duncan, Chief Executive Officer of The
Binding Site, said: "The inclusion of FLC levels in the IMWG guidelines is a
prestigious endorsement of the significance of our product in the diagnosis
and treatment of multiple myeloma and other plasma cell disorders. Not only
does the use of Freelite considerably improve the assessment of prognosis in
virtually every plasma cell disorder, it also increases the accuracy with
which diseases can be monitored, thus improving the overall quality of life
|SOURCE The Binding Site Limited|
Copyright©2009 PR Newswire.
All rights reserved